These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 36232710)

  • 41. Heterologous immunization with BNT162b2 followed by mRNA-1273 in dialysis patients: seroconversion and presence of neutralizing antibodies.
    Kohmer N; Rabenau HF; Ciesek S; Krämer BK; Göttmann U; Keller C; Rose D; Blume C; Thomas M; Lammert A; Lammert A
    Nephrol Dial Transplant; 2022 May; 37(6):1132-1139. PubMed ID: 35099023
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phenotypic and functional changes of T cell subsets after CoronaVac vaccination.
    Phoksawat W; Nithichanon A; Lerdsamran H; Wongratanacheewin S; Meesing A; Pipattanaboon C; Kanthawong S; Aromseree S; Yordpratum U; Laohaviroj M; Lulitanond V; Chareonsudjai S; Puthavathana P; Kamuthachad L; Kamsom C; Thapphan C; Salao K; Chonlapan A; Nawawishkarun P; Prasertsopon J; Overgaard HJ; Edwards SW; Phanthanawiboon S
    Vaccine; 2022 Nov; 40(48):6963-6970. PubMed ID: 36283898
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunity against Delta and Omicron variants elicited by homologous inactivated vaccine booster in kidney transplant recipients.
    Zhang L; Yang J; Lai C; Wan L; Xiong S; Kong W; Liu Z; Yu P; Chen M; Mai W; Khan SA; Deng M; Chen L; Lei Y; Zhou Q; Yu N; Li P; Chen Z; Ji T
    Front Immunol; 2022; 13():1042784. PubMed ID: 36700230
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Heterologous Booster Dose with CORBEVAX following Primary Vaccination with COVISHIELD Enhances Protection against SARS-CoV-2.
    Jaggaiahgari S; Munigela A; Mitnala S; Gujjarlapudi D; Simhadri V; D NR
    Vaccines (Basel); 2022 Dec; 10(12):. PubMed ID: 36560556
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Humoral and Cellular Immune Response After a 3-Dose Heterologous SARS-CoV-2 Vaccination Using the mRNA-BNT162b2 and Viral Vector Ad26COVS1 Vaccine in Hemodialysis Patients.
    Davidovic T; Schimpf J; Abbassi-Nik A; Stockinger R; Sprenger-Mähr H; Lhotta K; Zitt E
    Front Immunol; 2022; 13():907615. PubMed ID: 35812459
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
    Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
    Front Immunol; 2021; 12():793191. PubMed ID: 34975897
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dynamic of anti-spike receptor binding domain (RBD) levels and short-term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers.
    Kitro A; Sirikul W; Thongkum W; Soponpong S; Yasamut U; Kiratipaisarl W; Kosai A; Kasinrerk W; Tayapiwatana C; Srithanaviboonchai K
    Vaccine; 2022 May; 40(21):2915-2924. PubMed ID: 35430106
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?
    Scaggs Huang F
    J Pediatric Infect Dis Soc; 2022 Apr; 11(4):126. PubMed ID: 35394545
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Persistence and Protective Potential of SARS-CoV-2 Antibody Levels After COVID-19 Vaccination in a West Virginia Nursing Home Cohort.
    Smoot K; Yang J; Tacker DH; Welch S; Khodaverdi M; Kimble W; Wen S; Amjad A; Marsh C; Perrotta PL; Hodder S
    JAMA Netw Open; 2022 Sep; 5(9):e2231334. PubMed ID: 36098966
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of BTN162b2 and CoronaVac boosters on humoral and cellular immunity of individuals previously fully vaccinated with CoronaVac against SARS-CoV-2: A longitudinal study.
    Kuloğlu ZE; El R; Guney-Esken G; Tok Y; Talay ZG; Barlas T; Kuskucu MA; Albayrak Ö; Doğan Ö; Yavuz SŞ; Midilli K; Ergönül Ö; Can F
    Allergy; 2022 Aug; 77(8):2459-2467. PubMed ID: 35437772
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.
    Mallory RM; Formica N; Pfeiffer S; Wilkinson B; Marcheschi A; Albert G; McFall H; Robinson M; Plested JS; Zhu M; Cloney-Clark S; Zhou B; Chau G; Robertson A; Maciejewski S; Hammond HL; Baracco L; Logue J; Frieman MB; Smith G; Patel N; Glenn GM;
    Lancet Infect Dis; 2022 Nov; 22(11):1565-1576. PubMed ID: 35963274
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Longitudinal profile of neutralizing and binding antibodies in vaccinated and convalescent COVID-19 cohorts by chemiluminescent immunoassays.
    Dou X; Wang E; Jiang R; Li M; Xiong D; Sun B; Zhang X
    Immun Inflamm Dis; 2022 Jun; 10(6):e612. PubMed ID: 35634960
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Durable spike-specific T cell responses after different COVID-19 vaccination regimens are not further enhanced by booster vaccination.
    Maringer Y; Nelde A; Schroeder SM; Schuhmacher J; Hörber S; Peter A; Karbach J; Jäger E; Walz JS
    Sci Immunol; 2022 Dec; 7(78):eadd3899. PubMed ID: 36318037
    [TBL] [Abstract][Full Text] [Related]  

  • 54. B- and T-cell immune responses elicited by the Comirnaty® COVID-19 vaccine in nursing-home residents.
    Torres I; Albert E; Giménez E; Alcaraz MJ; Botija P; Amat P; Remigia MJ; Beltrán MJ; Rodado C; Huntley D; Olea B; Navarro D
    Clin Microbiol Infect; 2021 Nov; 27(11):1672-1677. PubMed ID: 34174397
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Potentiating the Cross-Reactive IFN-γ T Cell and Polyfunctional T Cell Responses by Heterologous GX-19N DNA Booster in Mice Primed with Either a COVID-19 mRNA Vaccine or Inactivated Vaccine.
    Seo YB; Ko A; Shin D; Kim J; Suh YS; Na J; Ryu JI; Lee S; Oh MJ; Sung YC
    Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298704
    [TBL] [Abstract][Full Text] [Related]  

  • 56. SARS-CoV-2 antibody and T cell responses one year after COVID-19 and the booster effect of vaccination: A prospective cohort study.
    Mak WA; Koeleman JGM; van der Vliet M; Keuren F; Ong DSY
    J Infect; 2022 Feb; 84(2):171-178. PubMed ID: 34896516
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Interval between prior SARS-CoV-2 infection and booster vaccination impacts magnitude and quality of antibody and B cell responses.
    Buckner CM; Kardava L; El Merhebi O; Narpala SR; Serebryannyy L; Lin BC; Wang W; Zhang X; Lopes de Assis F; Kelly SEM; Teng IT; McCormack GE; Praiss LH; Seamon CA; Rai MA; Kalish H; Kwong PD; Proschan MA; McDermott AB; Fauci AS; Chun TW; Moir S
    Cell; 2022 Nov; 185(23):4333-4346.e14. PubMed ID: 36257313
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The third inactivated vaccine booster dramatically enhanced SARS-CoV-2 antibody responses and did not influence the profile of prothrombotic antibody.
    Pan Y; Wang S; Liu G; Wang L; Yang L; Zeng X; Qian C; Lin J; Pan Z; Li Y
    J Med Virol; 2023 Jan; 95(1):e28356. PubMed ID: 36443279
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination.
    Hernández-Luis P; Aguilar R; Pelegrin-Pérez J; Ruiz-Olalla G; García-Basteiro AL; Tortajada M; Moncunill G; Dobaño C; Angulo A; Engel P
    Front Immunol; 2022; 13():816389. PubMed ID: 35464418
    [TBL] [Abstract][Full Text] [Related]  

  • 60. SARS-CoV-2 infection and vaccination trigger long-lived B and CD4+ T lymphocytes with implications for booster strategies.
    Mazzoni A; Vanni A; Spinicci M; Lamacchia G; Kiros ST; Rocca A; Capone M; Di Lauria N; Salvati L; Carnasciali A; Mantengoli E; Farahvachi P; Zammarchi L; Lagi F; Colao MG; Liotta F; Cosmi L; Maggi L; Bartoloni A; Rossolini GM; Annunziato F
    J Clin Invest; 2022 Mar; 132(6):. PubMed ID: 35139036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.